Literature DB >> 10837966

X-rays vs. carbon-ion tumor therapy: cytogenetic damage in lymphocytes.

M Durante1, S Yamada, K Ando, Y Furusawa, T Kawata, H Majima, T Nakano, H Tsujii.   

Abstract

PURPOSE: To measure chromosomal aberrations in peripheral blood lymphocytes from cancer patients treated with X-rays or carbon ions (C-ions). METHODS AND MATERIALS: Blood samples from patients diagnosed for esophageal or uterine cervical cancer were obtained before, during, and at the end of the radiation treatment. The novel technique of interphase chromosome painting was used to detect aberrations in prematurely condensed chromosomes 2 and 4. The fraction of aberrant lymphocytes was measured as a function of the dose to the tumor volume. For comparison, blood samples were also exposed in vitro to X-rays or to carbon ions accelerated at the HIMAC.
RESULTS: C-ions were more efficient than X-rays in the induction of chromosomal aberrations in vitro. In patients with similar pathologies, tumor positions, and radiation field sizes, however, C-ions induced a lower fraction of aberrant lymphocytes than X-rays during the treatment. The initial slope of the dose-response curve for the induction of chromosomal aberrations during the treatment was correlated to the relative decrease in the number of white blood cells and lymphocytes during the treatment.
CONCLUSION: C-ions induce a lower level of cytogenetic damage in lymphocytes than X-rays, reducing the risk of bone marrow morbidity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837966     DOI: 10.1016/s0360-3016(00)00455-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  New challenges in high-energy particle radiobiology.

Authors:  M Durante
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

2.  Harnessing radiation to improve immunotherapy: better with particles?

Authors:  Marco Durante; Silvia Formenti
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

3.  Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy.

Authors:  John G Eley; Thomas Friedrich; Kenneth L Homann; Rebecca M Howell; Michael Scholz; Marco Durante; Wayne D Newhauser
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-16       Impact factor: 7.038

Review 4.  Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments.

Authors:  Alexander Helm; Daniel K Ebner; Walter Tinganelli; Palma Simoniello; Alessandra Bisio; Valentina Marchesano; Marco Durante; Shigeru Yamada; Takashi Shimokawa
Journal:  Int J Part Ther       Date:  2018-09-21

Review 5.  Charged-particle therapy in cancer: clinical uses and future perspectives.

Authors:  Marco Durante; Roberto Orecchia; Jay S Loeffler
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

Review 6.  Assessing the risk of second malignancies after modern radiotherapy.

Authors:  Wayne D Newhauser; Marco Durante
Journal:  Nat Rev Cancer       Date:  2011-05-19       Impact factor: 60.716

Review 7.  Charged particles in radiation oncology.

Authors:  Marco Durante; Jay S Loeffler
Journal:  Nat Rev Clin Oncol       Date:  2009-12-01       Impact factor: 66.675

8.  Physics and biomedical challenges of cancer therapy with accelerated heavy ions.

Authors:  Marco Durante; Jürgen Debus; Jay S Loeffler
Journal:  Nat Rev Phys       Date:  2021-09-17

9.  MnSOD downregulation induced by extremely low 0.1 mGy single and fractionated X-rays and microgravity treatment in human neuroblastoma cell line, NB-1.

Authors:  Hiroko P Indo; Tsukasa Tomiyoshi; Shigeaki Suenaga; Kazuo Tomita; Hiromi Suzuki; Daisuke Masuda; Masahiro Terada; Noriaki Ishioka; Oleg Gusev; Richard Cornette; Takashi Okuda; Chiaki Mukai; Hideyuki J Majima
Journal:  J Clin Biochem Nutr       Date:  2015-07-11       Impact factor: 3.114

10.  Carbon ion radiation inhibits glioma and endothelial cell migration induced by secreted VEGF.

Authors:  Yang Liu; Yuanyuan Liu; Chao Sun; Lu Gan; Luwei Zhang; Aihong Mao; Yuting Du; Rong Zhou; Hong Zhang
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.